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The potential concern with using fixed dose inhaled corticosteroid (ICS) or ICS with
long acting beta-agonist (ICS/LABA) is the possibility that patients will stop using their
controller and become over-reliant on their short acting beta-agonist (SABA) reliever.
It has been suggested that underuse of preventers and overuse of relievers  may be a
possible contributor to asthma deaths (NRAD),1 which at least in the UK appears to
be  on  the increase.  In  addition,  such  a  regimen often entails  having  to use  two
different inhalers which may be confusing for patients. Notably, there is a temporal
relationship between the ratio of SABA to ICS use and increased monthly admission
rates for asthma in the UK.2 
One way of  obviating the discordance between controller  and reliever is  to have
them both in the same single inhaler in a symptom driven regimen using so-called
anti-inflammatory  reliever  therapy  (AIR)  with  budesonide/formoterol  (BUD/FM).
Indeed this is now acknowledged in current global asthma guidelines which advocate
the  use  of  needed  BUD/FM  across  all  treatment  steps  either  on  its  own  or  in
conjunction  with  maintenance  therapy  –  otherwise  known  as  maintenance  and
reliever therapy (i.e. MART).3 Another potential advantage of such a regimen is that it
avoids patients being left on unnecessarily high doses of ICS or ICS/LABA in the long
term.
The evidence to support  using AIR alone in mild persistent  asthma is  compelling
comprising four key randomised controlled trials (table). The pragmatic Novel START
trial  in  adults   showed  that  BUD/FM  Turbuhaler  dry  powder  inhaler  (DPI)
combination  used  on  demand  (PRN)  was  superior  to  PRN  salbutamol  (SALB)
pressurised metered dose inhaler (pMDI) and was non inferior to maintenance BUD
DPI on the primary outcome of  asthma exacerbations, as well as reducing overall
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inhaled  corticosteroid  (ICS)  exposure.4 The  other  pragmatic  trial  in  adults  was
PRACTICAL which found using BUD/FM Turbuhaler to be non-inferior versus BUD DPI
on the primary end point of exacerbations, again using a lower overall  ICS dose.5
Unsurprisingly, FeNO levels were 13% higher with AIR versus maintenance BUD in
NOVEL START and PRACTICAL, reflecting the higher ICS dose exposure with the latter.
This was supported by two other trials (SYGMA 1/2) in patients aged 12 and older
using the same AIR regimen where exacerbations were the primary end point in
SYGMA 1 and secondary in SYGMA 2.6,  7 In SYGMA 16 the primary outcome of well
controlled asthma weeks was 14% more likely with AIR versus terbutaline PRN but
36% less likely versus maintenance  budesonide, while  AIR exhibited 64% and 17%
fewer exacerbations respectively. It is worth noting that in SYGMA 1 weeks with well
controlled asthma were driven by on demand inhaler use such that BUD/FM AIR was
always  biased  against  maintenance  BUD.  Pointedly  in  all  four  studies  despite
abnormally high rates of adherence with maintenance BUD, using AIR was shown to
be non-inferior to BUD on exacerbations. Real world ICS adherence rates are in the
region of 29-46%. The observed differences in ACQ were all of small magnitude and
less than the minimal clinically important difference of 0.5.
Using BUD/FM as AIR plus maintenance (i.e. MART) is superior to using salbutamol or
formoterol  as  reliever  in  conjunction  with  maintenance  BUD/FM  in  terms  of
exacerbation  reduction.8 Moreover  using  BUD/FM  as  AIR  plus  maintenance  is
superior to fixed dose ICS/LABA with SABA in regards to exacerbation reduction along
with lower ICS exposure.9 Thus patients can simply escalate or de-escalate BUD/FM
as AIR +/-  maintenance as  a continuum of  inhaled therapy for  mild to moderate
asthma in keeping with current guidelines  3 (Figure). This makes sense as patients
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often flip  between mild  to  moderate  persistent  asthma over  time depending  on
prevailing extrinsic trigger factors – in other words use more AIR when you need it
and less when you don’t. The AIR regimen involves treating type 2 inflammation as
the underlying tenet of asthma control, which in turn empowers patients to be in
command of their own disease. Clearly this requires a degree of educational input to
explain  to  the  patient  the  role  of  treating  inflammation  and  smooth  muscle
constriction with the one inhaler. Our own experience is that most patients prefer to
use a single inhaler and be empowered to have control of their own disease. 
It  appears  that  we  have  inadvertently  missed  an  intermediate  step  in  asthma
guidelines,  namely  using  ICS/SALB  combination  instead  of  SALB  as  PRN  reliever
therapy – indeed a BUD/SALB Aerosphere pMDI formulation (PT027, AstraZeneca) is
currently  in  development  for  this  purpose.  This  would  also  ensure  perfect
concordance  between  preventer  and  reliever  when  used  as  AIR  like  BUD/FM.
BUD/SALB could also be used instead of SALB as AIR on top of any preventer such as
fixed dose maintenance ICS or ICS/LABA. However, this would still entail using two
separate and possibly different inhaler devices which is not as simple or intuitive as
using the same BUD/FM Turbuhaler device as AIR +/- maintenance.
One potential concern with using BUD/FM as AIR is that patients may be unable to
use the DPI device in the setting of acute asthma in terms of being able to generate a
sufficient  inspiratory  flow.  In  reality  few patients  can  use  their  salbutamol  pMDI
properly or would ever carry around a spacer to use in an emergency.10 There are
reassuring data in patients presenting to hospital with acute severe asthma where
98% of cases were able to generate sufficient peak inspiratory flow (i.e. > 30 l/min)
through  the  Turbuhaler  DPI  device,11 while  inhaling   terbutaline  via  Turbuhaler
4
produced an improved bronchodilator response compared to using pMDI plus large
volume spacer.12 
At least in Europe BUD/FM is delivered via DPIs of which there are currently three
available devices, namely Turbuhaler (AstraZeneca), Spiromax (Teva) and Easyhaler
(Orion). However, all of the data for AIR alone were derived for Turbuhaler, hence
other devices do not have the same indication. Beclomethasone/formoterol pMDI
and Nexthaler DPI (Chiesi) like BUD/FM have data and an indication supporting AIR
plus maintenance (MART) but not AIR alone, while fluticasone/formoterol pMDI and
breath actuated k-haler (Mundipharma) do not have any data on AIR or MART and
are  only  licensed  for  maintenance.  Hence,  at  present  the  simplest  regimen  for
patients is to use BUD/FM Turbuhaler as AIR +/- maintenance as a single inhaler.
We duly acknowledge that the FDA do not presently mandate the use of BUD/FM as
AIR +/-  maintenance therapy  because of  unfounded concerns  regarding  potential
overuse of LABA’s in terms of down-regulation and tachyphlyaxis. Higher doses of
LABA  like  SABA  may  also  produce  systemic  effects  such  as  tachycardia  and
hypokalaemia. Pointedly concomitant BUD reverses beta-2 receptor down-regulation
and  associated  sub-sensitivity  of  response  with  FM.13 Nonetheless  the  evidence
suggests that using BUD/FM as AIR +/- maintenance is a way of simplifying asthma
treatment  to  attain  optimal  long  term  control  along  with  less  ICS  exposure.  At
present AIR does not have a paediatric indication. 
1 
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BUD/FM PRN vs: 
ICS dose 
BUD/FM PRN vs 
BUD bid 
Adherence 
(to BUD bid) 
ACQ+ 




 ALB PRN = 51% lower 
(p < 0.001) 
 BUD bid = 12% 





 ALB PRN = - 0.15 
 BUD bid = 0.14 
PRACTICAL5  BUD bid = 31% lower 
(p < 0.05) 
40% lower 76%  BUD bid = 0.06 
 
SYGMA 16 
 TERB PRN = 64% 
lower (p < 0.001) 
 BUD bid = 17% lower 






 TERB PRN = - 0.15 
 BUD bid = 0.15 
SYGMA 27  BUD bid = 3% lower 
(p = 0.75) 
75% lower 63%  BUD bid = 0.15 
 
Legend 
ALB PRN – Albuterol on demand 
BUD bid – Budesonide 200ug twice daily 
BUD/FM PRN – Budesonide/Formoterol 200/6ug on demand 
TERB PRN – Terbutaline on demand 
*Exacerbations were the secondary end point in SYGMA 1 
+Minimal clinically important difference in ACQ is 0.5 
Table 1
Figure Legend  
Escalation and de-escalation of budesonide/formoterol (BUD/FM) combination as AIR +/- 
maintenance therapy for the treatment of mild to moderate persistent asthma, to achieve 
optimal long term control while reducing ICS exposure. 
 
Figure Legend
Budesonide/formoterol used as anti-inflammatory reliever   
• Patient centered flexible dosing 
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